PCI Synthesis - Ownership and Business Overview

Life ScienceCompany

PCI Synthesis Ownership

Who owns PCI Synthesis?

PCI Synthesis is owned by Seqens SAS. It was acquired on June 20, 2018.

PCI Synthesis Business Overview

Where is PCI Synthesis headquartered?

PCI Synthesis is headquartered in Newburyport, Massachusetts.

What sector is PCI Synthesis in?

PCI Synthesis is a life science company.

Life Science M&A Summary in 2018

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2018. The largest life science acquisition in 2018 was Shire - which was acquired by Takeda Pharmaceutical for $67.7B.

Join Mergr to view all 246 acquisitions of life science companies in 2018, including 44 acquisitions by private equity firms, and 202 by strategics.

PCI Synthesis, Inc.

9 Opportunity Way,
Newburyport, Massachusetts 01950
United States,
(978) 462-5555
www.pcisynthesis.com

PCI Synthesis, Inc. is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry.


 Subscribe to unlock this and 206,153
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.